Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging

<p>Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-...

Full description

Bibliographic Details
Main Author: Terry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton
Format: Article
Language:English
Published: Ivyspring International Publisher 2012-01-01
Series:Theranostics
Online Access:http://www.thno.org/v02p1185.htm
id doaj-14dcb2458a2c4bc8b349dd264c840866
record_format Article
spelling doaj-14dcb2458a2c4bc8b349dd264c8408662020-11-25T01:23:52ZengIvyspring International PublisherTheranostics1838-76402012-01-0121211851198Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound ImagingTerry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton<p>Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 &#176;C) and octafluoropropane (OFP, bp =-37 &#176;C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.</p>http://www.thno.org/v02p1185.htm
collection DOAJ
language English
format Article
sources DOAJ
author Terry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton
spellingShingle Terry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton
Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
Theranostics
author_facet Terry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton
author_sort Terry O. Matsunaga, Paul S. Sheeran, Samantha Luois, Jason E. Streeter, Lee B. Mullin, Bhaskar Banerjee, Paul A. Dayton
title Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
title_short Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
title_full Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
title_fullStr Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
title_full_unstemmed Phase-Change Nanoparticles Using Highly Volatile Perfluorocarbons: Toward a Platform for Extravascular Ultrasound Imaging
title_sort phase-change nanoparticles using highly volatile perfluorocarbons: toward a platform for extravascular ultrasound imaging
publisher Ivyspring International Publisher
series Theranostics
issn 1838-7640
publishDate 2012-01-01
description <p>Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vaporization has introduced the possibility of expanding the diagnostic and therapeutic capability of ultrasound contrast agents to beyond the vascular space. Our laboratories have developed phase-change nanoparticles (PCNs) from the highly volatile PFCs decafluorobutane (DFB, bp =-2 &#176;C) and octafluoropropane (OFP, bp =-37 &#176;C ) for acoustic droplet vaporization. Studies with commonly used clinical ultrasound scanners have demonstrated the ability to vaporize PCN emulsions with frequencies and mechanical indices that may significantly decrease tissue bioeffects. In addition, these contrast agents can be formulated to be stable at physiological temperatures and the perfluorocarbons can be mixed to modulate the balance between sensitivity to ultrasound and general stability. We herein discuss our recent efforts to develop finely-tuned diagnostic/molecular imaging agents for tissue interrogation. We discuss studies currently under investigation as well as potential diagnostic and therapeutic paradigms that may emerge as a result of formulating PCNs with low boiling point PFCs.</p>
url http://www.thno.org/v02p1185.htm
work_keys_str_mv AT terryomatsunagapaulssheeransamanthaluoisjasonestreeterleebmullinbhaskarbanerjeepauladayton phasechangenanoparticlesusinghighlyvolatileperfluorocarbonstowardaplatformforextravascularultrasoundimaging
_version_ 1725120211899645952